PDCD1 and head and neck squamous cell carcinoma: Agents targeting anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) have revolutionized HNSCC therapy, triggering huge investigations into the formation and regulation of the immunosuppressive tumor microenvironment [2].